Description
HS-10370 is an investigational medication currently being studied in clinical trials. It is being evaluated as a potential treatment for advanced solid tumors, including colorectal cancer (CRC), particularly in patients whose tumors have a specific type of KRAS mutation (G12C). The trials are in the early phase (Phase 1b) and are primarily focused on assessing the safety, tolerability, how the drug is processed by the body (pharmacokinetics), its potential effectiveness (activity), and how the immune system responds to it (immunogenicity) when used alongside other standard cancer treatments. HS-10370 is being tested in combination with various other anti-cancer therapies, such as chemotherapy agents (like 5-Fluorouracil, Capecitabine, Oxaliplatin, Leucovorin, Platinum) and other investigational drugs (like Adebrelimab, HS-20093, HS-20117). The goal of these early trials is to determine the best way to use HS-10370 and to understand its potential benefits and risks before moving to larger studies.
Mechanism of Action
HS-10370 is an investigational drug. The specific way it works (its mechanism of action) is currently being studied in clinical trials. It is being investigated for its potential to target processes involved in cancer growth and spread, especially in tumors with the KRAS G12C mutation. The trials aim to understand how HS-10370 interacts with the body and affects tumor cells when combined with other cancer treatments.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.